



Flexion Therapeutics, Inc.  
Investor Relations Department  
10 Mall Road  
Suite 301  
Burlington, MA 01803  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: FLXN

Last Trade:	25.04
Trade Time:	9:43 AM ET Dec 18, 2017
Change:	-0.18  (-0.703%)
Day Range	25.04 - 25.67
52-Week Range	16.51 - 32.25
Volume	45,079

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Dec 13, 2017*

[Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee](#)

*Dec 11, 2017*

[Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer](#)

*Dec 7, 2017*

[Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\) in Bilateral Osteoarthritis of the Knee](#)

*Dec 6, 2017*

[Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference](#)

*Dec 4, 2017*

[Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\) \(4\)](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

*Mar 10, 2017*

[Annual Report \(10-K\)](#)

*Apr 28, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 6, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 8, 2017*

[Quarterly Report \(10-Q\)](#)

*May 5, 2017*

[Quarterly Report \(10-Q\)](#)